Intuitive Surgical Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Intuitive Surgical wird ein jährliches Gewinn- und Umsatzwachstum von 11.5% bzw. 13.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.3% betragen.
Wichtige Informationen
11.5%
Wachstumsrate der Gewinne
11.2%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 13.4% |
| Zukünftige Eigenkapitalrendite | 14.3% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 15 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Intuitive Surgical: One Of The Best Business Models In The World, But Not At This Price
Nov 14Intuitive Surgical Q3: Da Vinci 5 Robot Set For 2025, But Overvalued
Oct 18Intuitive Surgical (NASDAQ:ISRG) Is Reinvesting At Lower Rates Of Return
Oct 04
Intuitive Surgical Offers Low Risk, High Return Despite Valuation Concerns
Sep 24What You Can Learn From Intuitive Surgical, Inc.'s (NASDAQ:ISRG) P/S
Sep 16Intuitive Surgical: Detached From Fundamentals
Aug 26Intuitive Surgical: A Lofty Price To Pay For Innovation, Wait For A Better Entry Point
Aug 20There May Be Underlying Issues With The Quality Of Intuitive Surgical's (NASDAQ:ISRG) Earnings
Jul 26Intuitive Surgical: Shares Surge, But Now Near Fair Value (Rating Downgrade)
Jul 12Does Intuitive Surgical (NASDAQ:ISRG) Deserve A Spot On Your Watchlist?
Jul 11There Are Reasons To Feel Uneasy About Intuitive Surgical's (NASDAQ:ISRG) Returns On Capital
Jun 25What Is Intuitive Surgical, Inc.'s (NASDAQ:ISRG) Share Price Doing?
Jun 10Intuitive Surgical: Sell Signals Abound
May 17Intuitive Surgical, Inc.'s (NASDAQ:ISRG) CEO Compensation Looks Acceptable To Us And Here's Why
Apr 19Intuitive Surgical: Growth And Margins Will Be Challenged In 2024
Apr 12Intuitive Surgical (NASDAQ:ISRG) Will Want To Turn Around Its Return Trends
Mar 27Is It Too Late To Consider Buying Intuitive Surgical, Inc. (NASDAQ:ISRG)?
Mar 11Intuitive Surgical, Inc.'s (NASDAQ:ISRG) Earnings Haven't Escaped The Attention Of Investors
Feb 09Intuitive Surgical: Buy A 'Little Slice' Of The Future
Jan 29Do Intuitive Surgical's (NASDAQ:ISRG) Earnings Warrant Your Attention?
Jan 25Intuitive Surgical: Strong Pre-Announced Q4 - Time To Harvest The Gain, Initiate With 'Sell'
Jan 13Some Investors May Be Worried About Intuitive Surgical's (NASDAQ:ISRG) Returns On Capital
Dec 10At US$318, Is Intuitive Surgical, Inc. (NASDAQ:ISRG) Worth Looking At Closely?
Nov 25Should You Be Adding Intuitive Surgical (NASDAQ:ISRG) To Your Watchlist Today?
Oct 25Are Intuitive Surgical, Inc. (NASDAQ:ISRG) Investors Paying Above The Intrinsic Value?
Sep 22What Does Intuitive Surgical, Inc.'s (NASDAQ:ISRG) Share Price Indicate?
Aug 04There Are Reasons To Feel Uneasy About Intuitive Surgical's (NASDAQ:ISRG) Returns On Capital
Jul 17Intuitive Surgical (NASDAQ:ISRG) Might Be Having Difficulty Using Its Capital Effectively
Apr 08Is There Now An Opportunity In Intuitive Surgical, Inc. (NASDAQ:ISRG)?
Jan 26There Are Reasons To Feel Uneasy About Intuitive Surgical's (NASDAQ:ISRG) Returns On Capital
Jan 08Is Intuitive Surgical, Inc. (NASDAQ:ISRG) Worth US$272 Based On Its Intrinsic Value?
Dec 03Intuitive Surgical: Risky Ahead Of Q3 Earnings
Oct 16Is It Too Late To Consider Buying Intuitive Surgical, Inc. (NASDAQ:ISRG)?
Oct 11Japanese regulatory agency clears Intuitive's single-port robotic surgical system
Sep 30Returns On Capital At Intuitive Surgical (NASDAQ:ISRG) Paint A Concerning Picture
Sep 26Intuitive Surgical: Fundamentally Fairly Valued, Technically Risky (Technical Analysis)
Sep 23Intuitive Surgical: Raising The Red Flag On The Hospital Industry
Aug 23Estimating The Intrinsic Value Of Intuitive Surgical, Inc. (NASDAQ:ISRG)
Jul 26Intuitive Surgical to report Q2 result amid persistent COVID-19 headwinds
Jul 20Should You Think About Buying Intuitive Surgical, Inc. (NASDAQ:ISRG) Now?
Jul 11Intuitive Surgical: Quite Invasive
Jul 06Returns On Capital Signal Tricky Times Ahead For Intuitive Surgical (NASDAQ:ISRG)
Jun 27Intuitive Surgical Is Getting Close To Fair Value After Years Of Overvaluation
Jun 20Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 10,980 | 2,842 | 3,727 | 4,335 | 25 |
| 12/31/2025 | 9,515 | 2,524 | 2,735 | 3,637 | 29 |
| 12/31/2024 | 8,141 | 2,165 | 2,066 | 3,285 | 29 |
| 9/30/2024 | 7,867 | 2,243 | 586 | 1,821 | N/A |
| 6/30/2024 | 7,573 | 2,094 | 420 | 1,663 | N/A |
| 3/31/2024 | 7,319 | 1,988 | 596 | 1,708 | N/A |
| 12/31/2023 | 7,124 | 1,798 | 750 | 1,814 | N/A |
| 9/30/2023 | 6,851 | 1,517 | 1,256 | 2,023 | N/A |
| 6/30/2023 | 6,665 | 1,425 | 1,178 | 1,858 | N/A |
| 3/31/2023 | 6,431 | 1,312 | 1,006 | 1,639 | N/A |
| 12/31/2022 | 6,222 | 1,322 | 958 | 1,491 | N/A |
| 9/30/2022 | 6,118 | 1,378 | 1,091 | 1,621 | N/A |
| 6/30/2022 | 5,964 | 1,435 | 1,310 | 1,739 | N/A |
| 3/31/2022 | 5,906 | 1,644 | 1,460 | 1,835 | N/A |
| 12/31/2021 | 5,710 | 1,705 | 1,750 | 2,089 | N/A |
| 9/30/2021 | 5,489 | 1,689 | 1,885 | 2,149 | N/A |
| 6/30/2021 | 5,163 | 1,623 | 1,662 | 1,922 | N/A |
| 3/31/2021 | 4,551 | 1,173 | 1,315 | 1,610 | N/A |
| 12/31/2020 | 4,358 | 1,061 | 1,143 | 1,485 | N/A |
| 9/30/2020 | 4,307 | 1,053 | 988 | 1,410 | N/A |
| 6/30/2020 | 4,358 | 1,136 | 1,088 | 1,532 | N/A |
| 3/31/2020 | 4,604 | 1,386 | 1,202 | 1,618 | N/A |
| 12/31/2019 | 4,479 | 1,379 | 1,173 | 1,598 | N/A |
| 9/30/2019 | 4,247 | 1,314 | 1,045 | 1,384 | N/A |
| 6/30/2019 | 4,040 | 1,210 | 1,008 | 1,307 | N/A |
| 3/31/2019 | 3,850 | 1,147 | 961 | 1,223 | N/A |
| 12/31/2018 | 3,724 | 1,128 | 982 | 1,170 | N/A |
| 9/30/2018 | 3,570 | 804 | 1,001 | 1,164 | N/A |
| 6/30/2018 | 3,457 | 810 | N/A | 1,198 | N/A |
| 3/31/2018 | 3,306 | 778 | N/A | 1,183 | N/A |
| 12/31/2017 | 3,138 | 671 | N/A | 1,144 | N/A |
| 9/30/2017 | 3,003 | 906 | N/A | 1,142 | N/A |
| 6/30/2017 | 2,878 | 819 | N/A | 1,057 | N/A |
| 3/31/2017 | 2,790 | 780 | N/A | 1,102 | N/A |
| 12/31/2016 | 2,707 | 738 | N/A | 1,087 | N/A |
| 9/30/2016 | 2,619 | 722 | N/A | 1,041 | N/A |
| 6/30/2016 | 2,522 | 678 | N/A | 952 | N/A |
| 3/31/2016 | 2,434 | 628 | N/A | 875 | N/A |
| 12/31/2015 | 2,367 | 589 | N/A | 806 | N/A |
| 9/30/2015 | 2,285 | 546 | N/A | 683 | N/A |
| 6/30/2015 | 2,250 | 502 | N/A | 654 | N/A |
| 3/31/2015 | 2,179 | 472 | N/A | 623 | N/A |
| 12/31/2014 | 2,132 | 419 | N/A | 665 | N/A |
| 9/30/2014 | 2,082 | 438 | N/A | 700 | N/A |
| 6/30/2014 | 2,031 | 471 | N/A | 753 | N/A |
| 3/31/2014 | 2,097 | 526 | N/A | 788 | N/A |
| 12/31/2013 | 2,244 | 671 | N/A | 880 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ISRGDas prognostizierte Gewinnwachstum (11.5% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: ISRGDie Erträge des Unternehmens (11.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.3% pro Jahr).
Hohe Wachstumserträge: ISRGDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ISRGDie Einnahmen des Unternehmens (13.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: ISRGDie Einnahmen des Unternehmens (13.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ISRGDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.3%).